Pugh W C, Manning J T, Butler J J
Department of Pathology, University of Texas M.D. Anderson Hospital and Tumor Institute, Houston 77030.
Am J Surg Pathol. 1988 Dec;12(12):907-17. doi: 10.1097/00000478-198812000-00002.
We report 16 cases of a distinctive, biologically aggressive variant of small lymphocytic lymphoma/leukemia (SLL/L) that is characterized by the diffuse proliferation of cells normally comprising the pseudoproliferation centers (so-called paraimmunoblasts). Demographically, the patients differed in no significant regard from patients with SLL/L of usual type. Rapidly progressive, generalized lymphadenopathy was the dominant clinical finding in 15 of the 16 patients; one patient presented with symptoms related to lymphomatous involvement of the stomach and regional lymph nodes. Splenomegaly was observed in five patients. Seven patients, two of whom had a history of indolent-phase chronic lymphocytic leukemia, had an absolute lymphocytosis at diagnosis. In most patients, bone marrow involvement was noted at diagnosis. It consisted predominantly of small lymphocytic infiltrates indistinguishable from those observed in SLL/L of usual type; significant paraimmunoblastic infiltration was infrequent and generally occurred late in the disease course. Immunohistochemical and cytogenetic study further substantiated the hypothesized relationship of these cases to SLL/L. Findings included (a) coexpression of sIg and Leu-1 antigen in the majority of cases and (b) the presence of a t(11;14) (q13;q32) chromosome translocation in two of three cases with analyzable metaphases. Although treatment protocols were not uniform, follow-up data indicated an accelerated clinical course. Eleven patients have died of their disease between 3 and 39 months after diagnosis; the median survival was 28 months.
我们报告了16例小淋巴细胞淋巴瘤/白血病(SLL/L)的一种独特的、具有生物学侵袭性的变异型,其特征是通常构成假增殖中心的细胞(所谓的副免疫母细胞)弥漫性增殖。从人口统计学角度来看,这些患者与普通类型的SLL/L患者没有显著差异。16例患者中有15例的主要临床发现是快速进展的全身性淋巴结病;1例患者表现出与胃部及区域淋巴结淋巴瘤浸润相关的症状。5例患者观察到脾肿大。7例患者在诊断时出现绝对淋巴细胞增多,其中2例有惰性期慢性淋巴细胞白血病病史。在大多数患者中,诊断时发现有骨髓受累。其主要由与普通类型SLL/L中观察到的难以区分的小淋巴细胞浸润组成;显著的副免疫母细胞浸润不常见,且一般发生在疾病病程后期。免疫组织化学和细胞遗传学研究进一步证实了这些病例与SLL/L的假设关系。研究结果包括:(a)大多数病例中sIg和Leu-1抗原共表达;(b)在可分析中期的3例病例中有2例存在t(11;14)(q13;q32)染色体易位。尽管治疗方案不统一,但随访数据表明临床病程加速。11例患者在诊断后3至39个月之间死于该病;中位生存期为28个月。